# CT-011 MAb in DLBCL Patients Following ASCT

> **NCT00532259** · PHASE2 · COMPLETED · sponsor: **CureTech Ltd** · enrollment: 72 (actual)

## Conditions studied

- Lymphoma, Large Cell, Diffuse
- Lymphoma, Mixed Cell, Diffuse
- Primary Mediastinal Large B-Cell Lymphoma

## Interventions

- **DRUG:** CT-011

## Key facts

- **NCT ID:** NCT00532259
- **Lead sponsor:** CureTech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532259, "CT-011 MAb in DLBCL Patients Following ASCT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00532259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*